Rchr
J-GLOBAL ID:201701017573113170
Update date: Feb. 01, 2024
Koga Takamasa
Koga Takamasa
Affiliation and department:
Job title:
Reserch Fellow
Other affiliations (1):
Research field (2):
Tumor biology
, Respiratory surgery
Research keywords (7):
Patient derived organoid
, Tumor organoid
, HER2
, KRAS
, Lung cancer
, 呼吸器外科学
, 腫瘍学
Research theme for competitive and other funds (2):
- 2019 - 2022 EGFR変異肺癌における小細胞肺癌への形質転換によるTKI耐性獲得機序の検索
- 2016 - 2019 Molecular targeted therapy against adenocarcinoma of the lung harboring MET exon 14 skipping mutation
Papers (67):
-
Akira Hamada, Kenichi Suda, Masaya Nishino, Keiko Obata, Hana Oiki, Tomoyo Fukami, Shota Fukuda, Toshio Fujino, Shuta Ohara, Takamasa Koga, et al. Secondary mutations of the EGFR gene that confer resistance to mobocertinib in EGFR exon 20 insertion. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2023
-
Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. Journal of hematology & oncology. 2022. 15. 1. 79-79
-
古賀 教将, 光冨 徹哉. 肺癌とKRAS その分子生物学と治療戦略. 肺癌. 2022. 62. 3. 188-199
-
須田 健一, 古賀 教将, 藤野 智大, 濱田 顕, 宗 淳一, 光冨 徹哉. TKI耐性2次的変異を同定する手法としてのBa/F3細胞モデルの有用性. 肺癌. 2022. 62. 3. 258-258
-
Akira Hamada, Kenichi Suda, Toshio Fujino, Masaya Nishino, Shuta Ohara, Takamasa Koga, Takanobu Kabasawa, Masato Chiba, Masaki Shimoji, Makoto Endoh, et al. Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC. JTO clinical and research reports. 2022. 3. 5. 100321-100321
more...
MISC (123):
-
古賀 教将, 須田 健一, 小原 秀太, 藤野 智大, 濱田 顕, 宗 淳一, 光冨 徹哉. KRAS G12C阻害剤の感受性ならびに耐性二次変異の検索. 肺癌. 2020. 60. 6. 533-533
-
宗 淳一, 富沢 健二, 小原 秀太, 藤野 智大, 濱田 顕, 古賀 教将, 西野 将矢, 千葉 眞人, 下治 正樹, 須田 健一, et al. 臨床病期I期肺扁平上皮癌における画像的特徴と治療成績の検討. 肺癌. 2020. 60. 6. 611-611
-
古賀 教将, 光冨 徹哉. 【ゲノム医療時代のがん 分子標的薬と診断薬研究「治療」の選択肢を広げる新しい標的、併用療法、横断的・マルチコンパニオン診断薬、リキッドバイオプシー】(第4章)より精密ながんゲノム医療を目指して 非小細胞肺がんのドライバー遺伝子を標的とした分子標的薬. 実験医学. 2020. 38. 15. 2567-2574
-
宗 淳一, 小原 秀太, 藤野 智大, 濱田 顕, 古賀 教将, 西野 将矢, 千葉 眞人, 須田 健一, 武本 智樹, 光冨 徹哉. 非小細胞肺癌に対する積極的縮小手術の適応と限界【International】臨床病期I期の充実型非小細胞肺癌患者における部分切除の臨床転帰(Clinical outcome of partial resection in the patients with completely solid non-small cell lung cancer of clinical stage I). 日本外科学会定期学術集会抄録集. 2020. 120回. SY-6
-
老木 華, 須田 健一, 西野 将矢, 千葉 眞人, 小原 秀太, 藤野 智大, 古賀 教将, 濱田 顕, 武本 智樹, 宗 淳一, et al. Nerve Integrity Monitoring(NIM)を用いて反回神経の走行を確認した右側大動脈弓を有する左上葉肺癌の1切除例. 日本外科学会定期学術集会抄録集. 2020. 120回. RS-1
more...
Lectures and oral presentations (4):
-
Activity of Tarloxotinib in HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance.
(19th World Conference on Lung Cancer 2019 2019)
-
Activity of novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance.
(19th World Conference on Lung Cancer 2018)
-
Can Limited Resection Be Accepted As an Alternative Treatment Option for Patients with Early Stage Small Cell Lung Cancer?
(18th World Conference on Lung Cancer 2017)
-
Recurrence and Survival Outcome After Segmentectomy for Non-Small Cell Lung Cacner: A Long-term Follow-up Study at Single Institute.
(17th World Conference on Lung Cancer 2016)
Education (2):
- 2016 - 2020 Kumamoto University Graduate School of Medical Science
- 2005 - 2011 Kumamoto University School of Medicine
Professional career (1):
- Ph.D. (Kumamoto University)
Work history (2):
- 2021/05 - 現在 University of Toronto Division of Thoracic Surgery
- 2017/07 - 2021/04 近畿大学医学部外科学教室呼吸器外科部門
Association Membership(s) (5):
日本外科学会
, 日本呼吸器内視鏡学会
, 日本肺癌学会
, 日本呼吸器外科学会
, IASLC
Return to Previous Page